Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Transplant recipients have a high risk to develop skin malignancies. This effect depends on
the one hand on the immunosuppressive drugs themselves and relates on the other hand on the
dosage. Based on the encouraging results of previous, retrospective studies on patients
treated with Sirolimus (SRL), these patients should be switched to an immunosuppressive
regime including SRL, decreasing the dosage of calcineurin-inhibitors or converting from
former immunosuppression. A conversion to a SRL-based therapy is effective in
immunosuppression and safe regarding graft and patient survival.
This study was designed to assess whether a switch to a SRL-immunosuppressive therapy
decreases the incidence/reoccurrence of skin neoplasm.